Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 8, 2009, Pages 580-586

  Zoppini, G ^a   Targher, G ^a   Chonchol, M ^b   Perrone, F ^a   Lippi, G ^a   Muggeo, M ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Chronic kidney disease; HDL C; Risk factors; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; CHRONIC DISEASE; DIABETIC NEPHROPATHY; EPIDEMIOLOGY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; UPREGULATION;

AGED; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHRONIC DISEASE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 69349088781     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.11.003     Document Type: Article

References (34)

1. Mogensen C.E., and Cooper M.E. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 21 (2004) 4-17
2. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49 (2006) 11-19
3. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6 (2006) 479-483
4. Lewis E.J. Treating hypertension in the patient with overt diabetic nephropathy. Semin Nephrol 27 (2007) 182-194
5. Fioretto P., Bruseghin M., Berto I., Gallina P., Manzato E., and Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol 17 4 Suppl. 2 (2006) S86-S89
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
8. Valmadrid C.T., Klein R., Moss S.E., and Klein B.E.K. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160 (2000) 1093-1100
9. Wahba I.M., and Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2 (2007) 550-562
10. Dalrymple L.S., and Kaysen G.A. The effects of lipoproteins on the development and progression of renal disease. Am J Nephrol 28 (2008) 723-731
11. Molitch M.E., Rupp D., and Carnethon M. Higher levels of HDL-C are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 29 (2006) 78-82
12. Rossi M.C., Nicolucci A., Pellegrini F., Comaschi M., Ceriello A., Cucinotta D., et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 23 (2008) 1278-1284
13. Stevens L.A., Coresh J., Greene T., and Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
14. Froissart M., Rossert J., Jacquot C., Paillard M., and Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16 (2005) 763-773
15. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., American Diabetes Association, et al. Nephropathy in diabetes. Diabetes Care 27 Suppl. 1 (2004) S79-S83
16. No authors listed. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98 (1991) 786-806
17. Targher G., Bertolini L., Zenari L., Lippi G., Pichiri I., Zoppini G., et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med 25 (2008) 45-50
18. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Pagano G., et al. Progression to overt nephropathy in type 2 diabetes. The Casale Monferrato Study. Diabetes Care 26 (2003) 2150-2155
19. Parving H.H. Diabetic nephropathy: prevention and treatment. Kidney Int 60 (2001) 2041-2055
20. Ravid M., Brosh D., Ravid-Safran D., Levy Z., and Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158 (1998) 998-1004
21. Obermayr R.P., Temml C., Knechtelsdorfer M., Gutjahr G., Kletzmayr J., Heiss S., et al. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 23 (2008) 1265-1273
22. Schaeffner E.S., Kurth T., Curhan G.C., Glynn R.J., Rexrode K.M., Baigent C., et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14 (2003) 2084-2091
23. Muntner P., Coresh J., Smith J.C., Eckfeldt J., and Klag M.J. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int 58 (2000) 293-301
24. Haroun M.K., Jaar B.G., Hoffman S.C., Comstock G.W., Klag M.J., and Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14 (2003) 2934-2941
25. Jafar T.H., Schmid C.H., Stark P.C., Toto R., Remuzzi G., Ruggenenti P., et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 18 (2003) 2047-2053
26. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
27. Strippoli G.F.M., Navaneethan S.D., Johnson D.W., Perkovic V., Pellegrini F., Nicolucci A., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ 336 (2008) 645-651
28. Movva R., and Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 54 (2008) 1-13
29. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
30. Meyers C.D., and Kashyap M.L. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol 19 (2004) 366-373
31. Metascreen Writing Committee, Bonadonna R.C., Cucinotta D., Fedele D., Riccardi G., and Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 29 (2006) 2701-2707
32. Avogaro A., Giorda C., Maggini M., Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30 (2007) 1241-1247
33. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J.P., Komajda M., et al., for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
34. Kastelein J.J.P., Adkim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhoef A.F.H., et al., for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443